Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study compared the efficacy of indacaterol versus placebo in COPD patients classified as GOLD 2014 Patient Group B. This was a 2-arm parallel group study that recruited COPD patients classified by GOLD Patient Gorup B. On successful completion of run-in period, patients were randomized in the ratio 1:1 to receive prn salbutamol plus: 1. Indacaterol 150ug or 2. Placebo for indacaterol all once daily (od) for 26 weeks. The primary objective (trough FEV1) was assessed after 12 weeks.
Epistemonikos ID: f9ec40c7d616f888fe0be6e22134747701bfb653
First added on: May 12, 2024